Zantac (Ranitidine) Recalls Remain Recommendation of European Medicines Agency
European regulators indicate recalls for Zantac and all ranitidine-based heartburn medications should remain in place throughout the European Union, due to the presence of a cancer-causing impurity known as N-nitrosodimethyylamine (NDMA).
The European Medicines Agency (EMA) recently issued a press release to announce it has confirmed prior recommendations to suspend ranitidine from the market. The statement came after one of the drug makers selling the generic Zantac requested the EMA re-examine its decision to ban the drug in April 2020.
Zantac (ranitidine) has been a widely used treatment for heartburn and acid reflux for decades, becoming the first medication to surpass $1 billion in annual sales in 1988. However, federal regulators in both the U.S. and the EU have now required Zantac recalls for all versions of the ranitidine-based medication, after discovering ranitidine is inherently unstable and may produce high levels of the cancer-causing chemical byproduct NDMA during storage or inside the human body.
Learn More About
Side effects of Zantac may increase the risk of cancer, due to chemical impurities found in the heartburn drug.Learn More About this Lawsuit See If You Qualify Now >
NDMA is a chemical byproduct, which was previously used to manufacture rocket fuel in the early 1990s. However, today, its only use is to cause cancer in animals as part of laboratory experiments.
In the EMA, the re-examination of Zantac safety was conducted by the human medicines committee (CHMP).
“Following the re-examination, the CHMP has maintained the conditions for lifting the suspension of the medicines, including requirements for companies to provide more data on the possible formation of NDMA from ranitidine inside the body,” the EMA stated. “The formation of NDMA in the body is expected to be very low following a single low dose of ranitidine given by injection or infusion (drip). Therefore, the CHMP slightly amended the conditions for lifting the suspension for those ranitidine medicines that are given by injection or infusion as a single, low dose.”
The contamination problems were first discovered by consumers and the medical community in September 2019, when the independent pharmacy Valisure conducted testing which found each pill may result in exposure to levels of NDMA substantially higher than the permissible daily intake limits set by the FDA.
Valisure testing found some 150 mg Zantac pills contained more than 3,000,000 nanograms (ng) of NDMA, even though the safe level set by the FDA is only 96 ng per day.
Thousands of Zantac lawsuits are now being pursued by former users of the medication diagnosed with breast cancer, testicular cancer, kidney cancer, stomach cancer and other health problems following years of exposure to NDMA in Zantac.
Given common questions of fact and law raised in complaints filed throughout the federal court system, the Zantac litigation has been centralized and consolidated in the U.S. District Court for the Southern District of Florida, where the cases are being overseen by U.S. District Judge Robin L. Rosenberg during coordinated discovery and pretrial proceedings.
PenelopeDecember 15, 2020 at 4:18 am
My husband Neil took Zantac for many years for acid reflux heartburn He got a pain every time he ate in August and saw our doctor in the first week of September CT scans and endoscopy biopsies revealed he had an aggressive cancer in the lesser stomach and at the junction of the esophagus A PET scan showed the cancer was contained within this area. Unfortunately the biopsies caused tremendous bl[Show More]My husband Neil took Zantac for many years for acid reflux heartburn He got a pain every time he ate in August and saw our doctor in the first week of September CT scans and endoscopy biopsies revealed he had an aggressive cancer in the lesser stomach and at the junction of the esophagus A PET scan showed the cancer was contained within this area. Unfortunately the biopsies caused tremendous blood loss and he had to have blood transfusions subsequently he then got a blood infection At the start of November he received his first chemo treatment and 2 weeks later on the 13th November his 2nd he passed away in the early hours of the 18th November he was just 52 We reside in Cyprus can he be included in the litigation his cancer was described as rare Are there any lawyers in Europe pursuing claims?
"*" indicates required fields
More Top Stories
Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.
More than 775 Exactech lawsuits have been filed in federal and state courts as parties work toward a plan for bellwether early test trials.
A federal judge has announced he will soon begin remanding 3M earplug lawsuits back to their originating districts for trials over claims of veteran hearing loss.